Clinical Significance of National Institutes of Health Classification in Patients With Chronic Prostatitis/Chronic Pelvic Pain Syndrome.
10.4111/kju.2014.55.4.276
- Author:
Yun Hsien SUNG
1
;
Jae Hung JUNG
;
Seung Hoon RYANG
;
Sung Jin KIM
;
Kwang Jin KIM
Author Information
1. Department of Urology, Yonsei University Wonju College of Medicine, Wonju, Korea. kkjksw@yonsei.ac.kr
- Publication Type:Original Article
- Keywords:
Adrenergic alpha-antagonist;
Anti-bacterial agents;
Leukocytes;
Prostatitis
- MeSH:
Anti-Bacterial Agents;
Classification*;
Consensus;
Humans;
Inflammation;
Leukocytes;
Levofloxacin;
National Institutes of Health (U.S.)*;
Pelvic Pain*;
Prostate;
Prostatitis;
Quality of Life;
Retrospective Studies
- From:Korean Journal of Urology
2014;55(4):276-280
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: We determined the effects of alpha-blockers and quinolone in patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) classified by National Institute of Health (NIH) consensus group. MATERIALS AND METHODS: Data from a total of 111 patients who were diagnosed with CP/CPPS between June 2010 and June 2012 were analyzed retrospectively. The patients were classified into group 1 (category IIIA, n=40) and group 2 (category IIIB, n=71). Treatment using alfuzosin and levofloxacin was given to both groups for 6 weeks. International Prostate Symptom Score (IPSS) and NIH Chronic Prostatitis Symptom Index were measured before and after therapy. RESULTS: Group 1 had a significant decrease in total IPSS score, CPSI pain score, CPSI quality of life (QoL) score, and total CPSI score (p=0.043, p=0.006, p=0.015, and p=0.006, respectively). Group 2 had a significant decrease in IPSS voiding symptom score, IPSS storage symptom score, total IPSS, CPSI pain score, CPSI voiding score, CPSI QoL score, and total CPSI score (p=0.002, p=0.004, p=0.001, p=0.001, p=0.006, p=0.001, and p=0.001, respectively). The CPSI score was reduced by 6 points or more in 50.0% of patients (n=18) in group 1 and in 51.6% of patients (n=32) in group 2. However, there was no statistically significant difference between the changes in IPSS and CPSI scores across the 2 groups. CONCLUSIONS: Although combination treatment reduced the CPSI score in both groups, there was no significant difference between the groups after combination treatment. We suggest that factors other than inflammation also contribute to symptoms associated with CP/CPPS.
